Anesthesiology
Review Panel
- CardiovascularReview Panel
- ChemistryReview Panel
- DentalReview Panel
- Ear, Nose, ThroatReview Panel
- Gastroenterology and UrologyReview Panel
- General HospitalReview Panel
- HematologyReview Panel
- ImmunologyReview Panel
- MicrobiologyReview Panel
- NeurologyReview Panel
- Obstetrical and GynecologicalReview Panel
- OphthalmicReview Panel
- OrthopedicReview Panel
- PathologyReview Panel
- MiscellaneousMiscellaneous
- Subpart B—Biological StainsCFR Sub-Part
- Subpart C—Cell And Tissue Culture ProductsCFR Sub-Part
- Subpart D—Pathology Instrumentation and AccessoriesCFR Sub-Part
- Subpart E—Immunology Laboratory Equipment and ReagentsCFR Sub-Part
- Subpart E—Specimen Preparation ReagentsCFR Sub-Part
- Subpart F—Automated and Semi-Automated Hematology DevicesCFR Sub-Part
- Subpart F—Immunological Test SystemsCFR Sub-Part
- Subpart G—Tumor Associated Antigen immunological Test SystemsCFR Sub-Part
- NQISystem, Immunomagnetic, Circulating Cancer Cell, Enumeration2Product Code
- NYIClassifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer2Product Code
- OVQChronic Lymphocytic Leukemia Fish Probe Kit2Product Code
- OWKEarly Growth Response 1 (Egr) Fish Probe Kit2Product Code
- OWMProstate-Specific Antigen (Psa) For Prognostic, Recurrence Risk Assessment Of Prostate Cancers2Product Code
- OXPDna-Probe Kit, Human Chromosome X And Y, Bmt Engraftment2Product Code
- OYXBcr/Abl1 Monitoring Test2Product Code
- QNCWhole Exome Sequencing Constituent Device2Product Code
- PZMNext Generation Sequencing Based Tumor Profiling Test2Product Code
- QDCDna-Based Test For Minimal Residual Disease For Hematologic Malignancies2Product Code
- Subpart H—Hematology Kits and PackagesCFR Sub-Part
- Subpart J—Products Used In Establishments That Manufacture Blood and Blood ProductsCFR Sub-Part
- Physical MedicineReview Panel
- RadiologyReview Panel
- General and Plastic SurgeryReview Panel
- ToxicologyReview Panel
- Medical GeneticsReview Panel
- UnknownReview Panel
Prostate-Specific Antigen (Psa) For Prognostic, Recurrence Risk Assessment Of Prostate Cancers
- Page Type
- Product Code
- Definition
- Determines rate of increase of total prostate specific antigen at ultrasensitive concentration levels (picogram/ml serum), and identifies those patients following prostatectomies which are at reduced risk for recurrence of prostate cancer.
- Physical State
- Capture antidbody, DNA-labeled antibody and PCR reagents. Software
- Technical Method
- Uses Immuno-PCR technology. Ultrasensitive levels (picograms/ml concentration) of total prostate specific antigen are captured in a sandwich immunoassay using DNA-labeled antibody. The sandwich is detected by Polymerase Chain Reaction exponential amplification. Rate of increase in PSA concentration over a time period is determined by computer software.
- Target Area
- Serum
- Regulation Medical Specialty
- Immunology
- Review Panel
- Pathology
- Submission Type
- 510(K)
- Device Classification
- Class 2
- Regulation Number
- 866.6040
- GMP Exempt?
- No
- Summary Malfunction Reporting
- Eligible
- Implanted Device
- No
- Life-Sustain/Support Device
- No
- Third Party Review
- Not Third Party Eligible
- MAUDE Alerts
- View and Sign Up For MAUDE Alerts
CFR § 866.6040 Gene expression profiling test system for breast cancer prognosis
§ 866.6040 Gene expression profiling test system for breast cancer prognosis.
(a) Identification. A gene expression profiling test system for breast cancer prognosis is a device that measures the ribonucleic acid (RNA) expression level of multiple genes and combines this information to yield a signature (pattern or classifier or index) to aid in prognosis of previously diagnosed breast cancer.
(b) Classification. Class II (special controls). The special control is FDA's guidance document entitled “Class II Special Controls Guidance Document: Gene Expression Profiling Test System for Breast Cancer Prognosis.” See § 866.1(e) for the availability of this guidance document.
[72 FR 26291, May 9, 2007]